BioChem Solutions Inc. Announces Initiation of Phase III Trials

MIAMI--(BUSINESS WIRE)--BioChem Solutions Inc. (Pink Sheets:BCHS) announced it has now committed to proceeding with the Phase III trials for Arthromir and Alphamir drugs that have been developed and derived from trioxolane as stated in a prior news release. This research is being conducted under FDA protocol guidelines at the Kenya Medical Institute (KEMRI). This research is piggy-backed onto the favorable results seen in the Phase II trials conducted in 2004.

MORE ON THIS TOPIC